Interleukin 1 (IL1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Interleukin 1 (IL1) – Pipeline Review, H2 2017’, provides in depth analysis on Interleukin 1 (IL1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 (IL1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Musculoskeletal Disorders, Metabolic Disorders, Oncology, Cardiovascular, Dermatology, Central Nervous System, Gastrointestinal, Genetic Disorders, Ear Nose Throat Disorders and Genito Urinary System And Sex Hormones under development targeting Interleukin 1 (IL1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)

The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Apexigen Inc

Exicure Inc

Immune Response BioPharma Inc

Moderna Therapeutics Inc

Novartis AG

Omnitura Therapeutics Inc

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

Orphit SAS

Peptinov SAS

Pfizer Inc

R Pharm

Regeneron Pharmaceuticals Inc

Spherium Biomed SL

Swedish Orphan Biovitrum AB

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Interleukin 1 (IL1) - Overview 8

Interleukin 1 (IL1) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 14

Products under Development by Universities/Institutes 19

Interleukin 1 (IL1) - Therapeutics Assessment 21

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Interleukin 1 (IL1) - Companies Involved in Therapeutics Development 28

AbbVie Inc 28

Apexigen Inc 28

Exicure Inc 28

Immune Response BioPharma Inc 29

Moderna Therapeutics Inc 29

Novartis AG 30

Omnitura Therapeutics Inc 30

Opsona Therapeutics Ltd 31

Optimum Therapeutics LLC 31

Orphit SAS 32

Peptinov SAS 32

Pfizer Inc 32

R Pharm 33

Regeneron Pharmaceuticals Inc 33

Spherium Biomed SL 34

Swedish Orphan Biovitrum AB 34

XBiotech Inc 34

Interleukin 1 (IL1) - Drug Profiles 36

ABT-981 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AC-203 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

AN-4161 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

APX-002 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

canakinumab - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

diacerein - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

diacerein CR - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

IR-1000 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

IR-1002 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

IR-888 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

melittin - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

mRNA-2752 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

OMN-54 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

PPV-01 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

rilonacept - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

RPH-104 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

SOBI-006 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

SP-15008 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

suramin hexasodium - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Xilonix - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Ymalzen - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Interleukin 1 (IL1) - Dormant Products 84

Interleukin 1 (IL1) - Discontinued Products 89

Interleukin 1 (IL1) - Product Development Milestones 92

Featured News & Press Releases 92

Nov 03, 2017: XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions 92

Nov 01, 2017: TWi Biotechnology Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting 92

Oct 27, 2017: Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America 93

Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer 93

Oct 03, 2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board 94

Sep 27, 2017: Castle Creek Pharmaceuticals Announces First IGA Scale for Epidermolysis Bullosa Simplex Clinical Research 95

Sep 15, 2017: Refusal of the marketing authorization for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech 95

Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 96

Aug 27, 2017: Anti-inflammatory drug could reduce risk of second heart attack 97

Aug 27, 2017: Anti-Inflammatory Therapy Cuts Risk of Lung Cancer 97

Aug 27, 2017: Inflammatory Hypothesis Confirmed: Reducing Inflammation Without Lowering Cholesterol Cuts Risk of Cardiovascular Events 99

Aug 27, 2017: Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned 101

Aug 27, 2017: Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk 102

Aug 07, 2017: Novartis’s Ilaris Rejects For Use Within NHS Scotland 104

Jun 22, 2017: Novartis Phase III study shows ACZ885 reduces cardiovascular risk in people who survived a heart attack 104

Appendix 105

Methodology 105

Coverage 105

Secondary Research 105

Primary Research 105

Expert Panel Validation 105

Contact Us 105

Disclaimer 106

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13

Number of Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18

Number of Products under Investigation by Universities/Institutes, H2 2017 19

Products under Investigation by Universities/Institutes, H2 2017 20

Number of Products by Stage and Mechanism of Actions, H2 2017 22

Number of Products by Stage and Mechanism of Actions, H2 2017 (Contd..1), H2 2017 23

Number of Products by Stage and Route of Administration, H2 2017 25

Number of Products by Stage and Molecule Type, H2 2017 27

Pipeline by AbbVie Inc, H2 2017 28

Pipeline by Apexigen Inc, H2 2017 28

Pipeline by Exicure Inc, H2 2017 29

Pipeline by Immune Response BioPharma Inc, H2 2017 29

Pipeline by Moderna Therapeutics Inc, H2 2017 29

Pipeline by Novartis AG, H2 2017 30

Pipeline by Omnitura Therapeutics Inc, H2 2017 31

Pipeline by Opsona Therapeutics Ltd, H2 2017 31

Pipeline by Optimum Therapeutics LLC, H2 2017 32

Pipeline by Orphit SAS, H2 2017 32

Pipeline by Peptinov SAS, H2 2017 32

Pipeline by Pfizer Inc, H2 2017 33

Pipeline by R Pharm, H2 2017 33

Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 33

Pipeline by Spherium Biomed SL, H2 2017 34

Pipeline by Swedish Orphan Biovitrum AB, H2 2017 34

Pipeline by XBiotech Inc, H2 2017 35

Dormant Products, H2 2017 84

Dormant Products, H2 2017 (Contd..1), H2 2017 85

Dormant Products, H2 2017 (Contd..2), H2 2017 86

Dormant Products, H2 2017 (Contd..3), H2 2017 87

Dormant Products, H2 2017 (Contd..4), H2 2017 88

Discontinued Products, H2 2017 89

Discontinued Products, H2 2017 (Contd..1), H2 2017 90

Discontinued Products, H2 2017 (Contd..2), H2 2017 91

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 21

Number of Products by Stage and Mechanism of Actions, H2 2017 21

Number of Products by Routes of Administration, H2 2017 24

Number of Products by Stage and Routes of Administration, H2 2017 24

Number of Products by Molecule Types, H2 2017 26

Number of Products by Stage and Molecule Types, H2 2017 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports